Compare Stocks: STTK, VRDN, SLS, and PHVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PHVS Pharvaris	$33.07 -6.1%	$35.36	$20.65 ▼ $43.25	$2.30B	-2.33	1.04 million shs	654,170 shs
SLS SELLAS Life Sciences Group	$11.52 -4.2%	$12.44	$1.39 ▼ $15.88	$2.43B	2.52	6.97 million shs	3.85 million shs
STTK Shattuck Labs	$6.36 -2.2%	$7.00	$1.70 ▼ $8.33	$652.36M	1.09	1.10 million shs	1.39 million shs
VRDN Viridian Therapeutics	$21.43 -3.1%	$21.85	$13.18 ▼ $34.29	$2.51B	0.97	1.38 million shs	2.86 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PHVS Pharvaris	-6.05%	-11.93%	-11.36%	-0.69%	+32.81%
SLS SELLAS Life Sciences Group	-4.16%	-1.20%	-19.55%	+9.40%	+577.65%
STTK Shattuck Labs	-2.15%	+8.16%	-19.49%	+7.61%	+166.11%
VRDN Viridian Therapeutics	-3.12%	-4.50%	-10.78%	+23.23%	+9.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PHVS Pharvaris	$33.07 -6.1%	$35.36	$20.65 ▼ $43.25	$2.30B	-2.33	1.04 million shs	654,170 shs
SLS SELLAS Life Sciences Group	$11.52 -4.2%	$12.44	$1.39 ▼ $15.88	$2.43B	2.52	6.97 million shs	3.85 million shs
STTK Shattuck Labs	$6.36 -2.2%	$7.00	$1.70 ▼ $8.33	$652.36M	1.09	1.10 million shs	1.39 million shs
VRDN Viridian Therapeutics	$21.43 -3.1%	$21.85	$13.18 ▼ $34.29	$2.51B	0.97	1.38 million shs	2.86 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PHVS Pharvaris	-6.05%	-11.93%	-11.36%	-0.69%	+32.81%
SLS SELLAS Life Sciences Group	-4.16%	-1.20%	-19.55%	+9.40%	+577.65%
STTK Shattuck Labs	-2.15%	+8.16%	-19.49%	+7.61%	+166.11%
VRDN Viridian Therapeutics	-3.12%	-4.50%	-10.78%	+23.23%	+9.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PHVS Pharvaris	2.80	Moderate Buy	$59.87	81.03% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-13.19% Downside
STTK Shattuck Labs	3.00	Buy	$12.78	100.91% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.69	80.55% Upside

Current Analyst Ratings Breakdown

Latest STTK, VRDN, SLS, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
9/14/2026	VRDN Viridian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$65.00
9/11/2026	STTK Shattuck Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/10/2026	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $44.00
9/9/2026	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$42.00 ➝ $50.00
9/9/2026	PHVS Pharvaris	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$50.00 ➝ $65.00
9/9/2026	PHVS Pharvaris	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
9/9/2026	PHVS Pharvaris	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $62.00
9/9/2026	PHVS Pharvaris	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$79.00
9/9/2026	PHVS Pharvaris	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$55.00 ➝ $65.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A
STTK Shattuck Labs	$1M	638.31	N/A	N/A	$1.30 per share	4.89
VRDN Viridian Therapeutics	$70.85M	34.27	N/A	N/A	$6.18 per share	3.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest STTK, VRDN, SLS, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PHVS Pharvaris	N/A	11.94	11.94
SLS SELLAS Life Sciences Group	N/A	18.83	18.83
STTK Shattuck Labs	N/A	27.59	27.59
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PHVS Pharvaris	N/A
SLS SELLAS Life Sciences Group	17.38%
STTK Shattuck Labs	58.74%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
PHVS Pharvaris	11.84%
SLS SELLAS Life Sciences Group	1.30%
STTK Shattuck Labs	8.79%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PHVS Pharvaris	148	65.41 million	57.66 million	Not Optionable
SLS SELLAS Life Sciences Group	13	201.95 million	199.32 million	Not Optionable
STTK Shattuck Labs	40	100.36 million	91.54 million	Optionable
VRDN Viridian Therapeutics	252	113.29 million	110.57 million	Optionable

STTK, VRDN, SLS, and PHVS Headlines

Recent News About These Companies

Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)

September 23 at 11:31 AM | theglobeandmail.com

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

September 22 at 11:55 PM | finance.yahoo.com

Viridian Therapeutics: Two Products, One Commercial Buildout

September 17, 2026 | seekingalpha.com

Squarepoint Ops LLC Purchases 133,046 Shares of Viridian Therapeutics, Inc. $VRDN

September 13, 2026 | marketbeat.com

Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

September 8, 2026 | globenewswire.com

Legal & General Group Plc Takes Position in Viridian Therapeutics, Inc. $VRDN

September 8, 2026 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 5, 2026 | marketbeat.com

268,060 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Bank of New York Mellon Corp

September 5, 2026 | marketbeat.com

Wellington Management Group LLP Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

September 4, 2026 | marketbeat.com

Velan Capital Investment Management LP Has $184,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

September 3, 2026 | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026 | finance.yahoo.com

The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

September 2, 2026 | marketbeat.com

Yiheng Capital Management L.P. Has $7.36 Million Holdings in Viridian Therapeutics, Inc. $VRDN

August 31, 2026 | marketbeat.com

Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN

August 27, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $25.31 Million Investment in Viridian Therapeutics, Inc. $VRDN

August 25, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

August 8, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

STTK, VRDN, SLS, and PHVS Company Descriptions

Pharvaris NASDAQ:PHVS

$33.07 -2.13 (-6.05%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$33.09 +0.02 (+0.06%)

As of 09/23/2026 07:42 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

SELLAS Life Sciences Group NASDAQ:SLS

$11.52 -0.50 (-4.16%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$11.54 +0.02 (+0.21%)

As of 09/23/2026 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Shattuck Labs NASDAQ:STTK

$6.36 -0.14 (-2.15%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$6.36 +0.00 (+0.08%)

As of 09/23/2026 07:30 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Viridian Therapeutics NASDAQ:VRDN

$21.43 -0.69 (-3.12%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$21.42 -0.01 (-0.05%)

As of 09/23/2026 07:30 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, VRDN, SLS, and PHVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, VRDN, SLS, and PHVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, VRDN, SLS, and PHVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STTK, VRDN, SLS, and PHVS Company Descriptions

Pharvaris NASDAQ:PHVS

SELLAS Life Sciences Group NASDAQ:SLS

Shattuck Labs NASDAQ:STTK

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, VRDN, SLS, and PHVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, VRDN, SLS, and PHVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, VRDN, SLS, and PHVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STTK, VRDN, SLS, and PHVS Company Descriptions

Pharvaris NASDAQ:PHVS

SELLAS Life Sciences Group NASDAQ:SLS

Shattuck Labs NASDAQ:STTK

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools